Bisphosphonates are widely used to manage osteoporosis in adults. In children, however, bisphosphonate use has been limited because of scarce data regarding its long-term effects on statural growth. In the pediatric literature, clinical data supporting the use of bisphosphonates in managing metabolic bone disease in children are sparse and largely anecdotal. Although more studies are available on conditions such as osteogenesis imperfecta and osteoporosis, additional studies are needed for fibrodysplasia ossificans progressiva, fibrous dysplasia, mucolipidosis type III, and
Legg-Calvé-Perthes disease.